FGFR4 and metabolic dysfunction-associated steatohepatitis: The results from phase 2b trials (e.g., NCT04171765) where administration of FGFR1c/KLB specific antibodies (240) are subjected to NASH patients will reveal more details on the contribution from the FGFR4/KLB complex to NASH resolution and lowering of fibrosis.